← FDA DRUG APPROVALS

FDA ANDA · ANDA204077

MYCOPHENOLATE MOFETIL

Sponsor: ZHEJIANG HISUN PHARM

APPLICATION
ANDA204077
TYPE
ANDA
ORIGINAL APPROVAL
2017-11-13
LATEST ACTION
2026-07-29
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

MYCOPHENOLATE MOFETILPrescription
MYCOPHENOLATE MOFETIL 250MG · CAPSULE · ORAL

Approval history

2026-07-29REMS · Supplement 8AP
2024-08-13REMS · Supplement 7AP
2024-06-06Labeling · Supplement 6 · standardAP
2024-06-06Labeling · Supplement 5 · standardAP
2021-08-11REMS · Supplement 4AP
2021-04-21REMS · Supplement 3AP
2021-01-15REMS · Supplement 2AP
2019-06-19Manufacturing (CMC) · Supplement 1 · unknownAP
2017-11-13UNKNOWN · OriginalREMSAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →